November 2, 2010 - Charleston Laboratories, Inc. Awarded a Qualifying Therapeutic Discovery Project Grant

May 18, 2009 - Charleston Laboratories, Inc. Completes Exploratory Bioequivalence Study of CL-108

April 28, 2009 - Charleston Laboratories, Inc. Appoints Kerry Segal Chief Business Development Advisor

Feburary 12, 2009 - Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire

February 2, 2009 - Charleston Completes Preliminary Research on Nausea-Prone Questionnaire (NPQ)

January 12, 2009 - Charleston begins Bioequivalence Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CL-108

January 12-15, 2009 - Charleston Laboratories Inc, has been invited and will be attending the 27th Annual J.P. Morgan Healthcare Conference, January 12-15, 2009 in San Francisco. This event is the premier conference of its kind, bringing together established industry leaders, emerging fast-growth companies, innovative technology creators and globally minded service providers.

January 9, 2009 - Charleston Sucessfully Completes Series A Private Placement

October 3, 2008 - Charleston Laboratories, Inc. Investigational New Drug CL-108 "Safe to Proceed Testing in Man."

November 8, 2007 - Charleston completes successful Type B, Pre-IND meeting with FDA's Division of Anesthesia,
Analgesia and Rheumatology Products on November 8, 2007, held at FDA's Silver Spring, Maryland offices.

August 1, 2007 - Charleston Laboratories, Inc. Appoints Bernard Schachtel, M.D. Chief Medical Officer

August 1, 2007 - Charleston Laboratories, Inc. Appoints John F. Ameling V.P of Regulatory Affairs